Both drugs work. Both produce real, significant weight loss. But the data shows one pulls ahead, and it is not close.
Here is what the research says, what the differences actually mean for your body, and how to think about which one makes sense for you. structured resistance training
Which Medication Causes More Weight Loss, Mounjaro or Wegovy?
Mounjaro produces more weight loss. Full stop.
In the SURMOUNT-1 trial, people taking tirzepatide (Mounjaro) at the highest dose lost an average of 22.5% of their body weight over 72 weeks. That is roughly 52 pounds for someone starting at 230 pounds. Both are injectable weight loss injections administered weekly.
In the STEP 1 trial, semaglutide (Wegovy) at its highest dose produced an average of 14.9% body weight loss over 68 weeks.
That gap is not small. It is about 7 to 8 percentage points of body weight. For most people, that is 15 to 20 extra pounds lost on Mounjaro compared to Wegovy.
A 2023 head-to-head observational study published in JAMA Internal Medicine confirmed this in real-world patients. People on tirzepatide lost significantly more weight at 3, 6, and 12 months compared to those on semaglutide.
In my experience reviewing this data, the difference is consistent across studies. It is not a fluke from one trial.
How Do Mounjaro and Wegovy Work Differently?
This is where it gets interesting, and it explains the weight loss gap.
Wegovy contains semaglutide. It works by mimicking one hormone called GLP-1 (glucagon-like peptide-1). GLP-1 slows digestion, reduces appetite, and tells your brain you are full. It also improves insulin sensitivity. Newer triple-hormone drugs are also emerging in this space. newer triple-hormone drugs
Mounjaro contains tirzepatide. It mimics two hormones, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP receptors sit in fat tissue and the brain. When you activate both pathways together, you get stronger appetite suppression, better fat burning, and more metabolic improvement than hitting just one receptor.
Think of it this way. Wegovy hits one target. Mounjaro hits two. The dual action is why the weight loss numbers are higher.
What I found in the research is that GIP activation also seems to reduce the nausea side effects that come with GLP-1 stimulation alone. So Mounjaro may actually be better tolerated at higher doses, which is part of why people can push to the maximum dose more often.
Is Mounjaro FDA-Approved for Weight Loss Like Wegovy?
This is an important distinction.
Wegovy received FDA approval specifically for chronic weight management in adults with obesity or overweight with a weight-related condition. That approval came in June 2021.
Mounjaro received FDA approval for type 2 diabetes management in May 2022. As of late 2023, the FDA approved tirzepatide under the brand name Zepbound specifically for weight loss in people without diabetes.
So if your doctor prescribes Mounjaro for weight loss and you do not have diabetes, that is technically off-label use of Mounjaro. Zepbound is the on-label version for weight management. They contain the same drug at the same doses.
In practice, many doctors prescribe Mounjaro off-label for weight loss because the drug is identical to Zepbound. The approval status matters more for insurance coverage than for the actual medicine you are taking.
When I looked at this question from a first principles standpoint, the FDA approval difference is mostly a regulatory and insurance issue, not a safety or effectiveness issue. The molecule is the same.
Do Mounjaro and Wegovy Have Similar Side Effects?
Yes, the side effect profiles overlap heavily because both drugs activate GLP-1 receptors.
The most common side effects for both include nausea, vomiting, diarrhea, constipation, and stomach pain. These are most intense when you first start or increase your dose, and they usually settle down within a few weeks.
In the SURMOUNT-1 trial, about 44% of people on the highest tirzepatide dose reported nausea. In the STEP 1 trial, about 44% of people on semaglutide reported nausea too. So the rates are similar.
What I saw in the data is that serious side effects are rare but real for both drugs. These include pancreatitis, gallbladder problems, and a theoretical risk of thyroid tumors that showed up in animal studies. Neither drug is recommended if you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
One practical difference is that Mounjaro seems to cause slightly less nausea at equivalent weight loss doses, likely because the GIP component moderates the GLP-1 side effects. This means more people can tolerate the higher doses of Mounjaro, which contributes to the better weight loss outcomes.
Both drugs require a slow dose escalation over several months to minimize side effects. You do not start at the maximum dose.
Which Is More Expensive, Mounjaro or Wegovy?
Both are expensive without insurance coverage.
Wegovy has a list price of around $1,350 per month in the United States. Mounjaro sits at around $1,000 to $1,100 per month at list price.
Zepbound, the weight loss version of tirzepatide, launched at around $1,060 per month.
With insurance, costs vary dramatically. Some plans cover one but not the other. Medicare in the US does not cover either for weight loss as of early 2024, though this is changing.
Manufacturer savings programs exist for both. Eli Lilly offers savings cards for Mounjaro and Zepbound that can bring costs down to $25 to $550 per month depending on your situation. Novo Nordisk has similar programs for Wegovy.
Outside the US, pricing is different. In Australia, neither drug is currently on the Pharmaceutical Benefits Scheme for weight loss, so out-of-pocket costs apply. Prices vary by pharmacy and formulation.
The cost question is real and it matters. What I found is that the price difference between the two drugs is not large enough to be the deciding factor if one is clearly better suited to your health profile. The bigger issue is whether either is covered by your insurance or health plan.
Can You Switch from Wegovy to Mounjaro for Better Results?
Yes, and some people do exactly this.
The most common reason to switch is hitting a weight loss plateau on Wegovy. When I tried to understand why this happens, the answer comes back to the mechanism. If you have maxed out the GLP-1 pathway and your body has adapted, adding GIP receptor activation through tirzepatide can restart progress.
A 2023 case series and several clinical observations show that people who switch from semaglutide to tirzepatide often see renewed weight loss, even after stalling on Wegovy for months.
The switch is not complicated from a medical standpoint. You stop one and start the other at a low dose, then titrate up. Your doctor will guide the timing.
What I found is that switching makes the most sense when you have been on the maximum tolerated dose of Wegovy for at least 3 to 6 months and weight loss has stopped. If you are still losing weight on Wegovy, there is no strong reason to switch.
The reverse switch, from Mounjaro to Wegovy, is less common because Mounjaro generally produces better results. It might happen due to cost, availability, or side effect differences in individual cases.
So Is Mounjaro or Wegovy More Effective?
Based on the clinical trial data and real-world evidence, Mounjaro (tirzepatide) produces more weight loss than Wegovy (semaglutide) in most people.
The numbers are clear. Around 22% body weight loss versus around 15%. That gap holds up across multiple studies and in real-world patient data.
The reason is the dual hormone mechanism. Two receptor targets produce stronger appetite suppression and better metabolic effects than one.
That said, Wegovy is not a weak drug. A 15% reduction in body weight is clinically significant and produces real health improvements. For some people, Wegovy is the right choice based on cost, insurance coverage, availability, or individual response.
The question of whether is Mounjaro or Wegovy more effective has a clear answer in the data, but the right drug for you depends on your health history, what your doctor recommends, and what you can actually access and afford.
FAQ
Is Mounjaro stronger than Wegovy?
Yes. Tirzepatide (Mounjaro) produces greater average weight loss than semaglutide (Wegovy) in clinical trials. The SURMOUNT-1 trial showed 22.5% body weight loss versus 14.9% in the STEP 1 trial for Wegovy.
Can I take Mounjaro if I do not have diabetes?
Yes. Zepbound is the FDA-approved version of tirzepatide for weight loss in people without diabetes. Mounjaro is the same drug approved for type 2 diabetes. Many doctors prescribe Mounjaro off-label for weight loss.
How long does it take to see results on Mounjaro or Wegovy?
Most people see noticeable weight loss within 4 to 8 weeks of starting. Significant results build over 6 to 12 months as the dose increases. Both drugs require slow dose escalation over several months.
Do you regain weight when you stop Mounjaro or Wegovy?
Yes. Research shows that most people regain a significant portion of lost weight within one to two years of stopping either drug. Both medications work while you take them. They are not a permanent fix without ongoing use or lifestyle changes that support the results.
Which drug has fewer side effects, Mounjaro or Wegovy?
Side effect rates are similar. Both cause nausea, vomiting, and digestive issues, especially early on. Some data suggests tirzepatide may cause slightly less nausea at equivalent doses due to the GIP component, which may help people tolerate higher doses better.
Can a personal trainer help while I am on Mounjaro or Wegovy?
Yes, and this matters more than most people realise. Both drugs reduce appetite and body weight, but they do not preserve muscle mass on their own. Research shows that a significant portion of weight lost on GLP-1 drugs can come from muscle, not just fat. Structured resistance training with guidance from an online personal trainer helps protect muscle while you lose fat, which improves your body composition and long-term metabolic health.
